[Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon]

Recenti Prog Med. 2002 Mar;93(3):183-5.
[Article in Italian]
No abstract available

MeSH terms

  • Androgen Antagonists / administration & dosage
  • Androgen Antagonists / therapeutic use*
  • Anilides / administration & dosage
  • Anilides / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Disease-Free Survival
  • Follow-Up Studies
  • Humans
  • Lymphatic Metastasis
  • Male
  • Nitriles
  • Prostate-Specific Antigen / blood
  • Prostatectomy*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / surgery*
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Time Factors
  • Tosyl Compounds

Substances

  • Androgen Antagonists
  • Anilides
  • Antineoplastic Agents
  • Nitriles
  • Tosyl Compounds
  • bicalutamide
  • Prostate-Specific Antigen